Papers I Editorials and Letters to the Editor I Abstract and Poster Sessions I Textbooks I Textbook Chapters

Papers:

Butler WM and Merrick GS. I-125 Rapid Strand™ Loading Technique. Rad Onc Invest 1996; 4:48-49. 

Merrick GS, Butler WM, Dorsey AT, Walbert HL. Prostatic Conformal Brachytherapy: I-125/Pd-103 Postoperative Dosimetric Analysis. Rad Onc Invest 1997; 5:305-313.

Butler WM, Dorsey AT, Nelson KR, Merrick GS. Quality Assurance Calibration of I-125 Rapid Strand™ in a Sterile Environment. Int J Radiat Oncol Biol Phys 1998; 41:217-222.

Merrick GS, Butler WM, Farthing W, Dorsey AT, Adamovich E. The Impact of Gleason Score Accuracy as a Criterion for Patient Selection in Prostate Brachytherapy. J Brachy Int 1998; 14:113-121.

Merrick GS, Butler WM, Dorsey AT, Walbert HL. The Influence of Timing on the Dosimetric Analysis of Transperineal Ultrasound Guided Prostatic Conformal Brachytherapy. Rad Onc Invest 1998; 6(4):182-190.

Merrick GS, Butler WM, Dorsey AT, Lief JH, Walbert HL, Blatt HJ. Rectal Dosimetric Analysis Following Prostate Brachytherapy. Int J Radiat Onc Biol Phys 1999; 43(5):1021-1027.

Abel LJ, Blatt HJ, Stipetich RL, Fuscardo JA, Zeroski D, Miller SE, Dorsey AT, Butler WM, Merrick GS. Nursing Management of Patients Receiving Brachytherapy for Early Stage Prostate Cancer. Clin J Oncol Nursing 1999; 3(1):7-15.

Merrick GS, Butler WM, Dorsey AT, Lief JH. The Potential Role of Various Dosimetric Quality Indicators in Prostate Brachytherapy. Int J Radiat Onc Biol Phys 1999; 44 (3):717-724.

Merrick GS, Butler, WM, Lief JH, Stipetich RL, Abel LJ, Dorsey AT. The Efficacy of Sildenafil Citrate in Prostate Brachytherapy Patients with Erectile Dysfunction. Urol 1999; 53:1112-1116.

Merrick GS, Butler WM, Dorsey AT, Lief JH. The Dependence of Prostate Post-Implant Dosimetric Quality on CT Volume Determination. Int J Radiat Onc Biol Phys 1999; 44:1111-1117.

Merrick GS, Butler WM, Dorsey AT, Lief JH, Benson ML. Seed Fixity in the Prostate/Periprostatic Region Following Brachytherapy. Int J Radiat Onc Biol Phys 2000; 46:215-220.

 

Butler WM, Merrick GS, Lief JH, Dorsey AT. Comparison of Seed Loading Approaches in Prostate Brachytherapy. Med Phys 2000; 27:381-392.

 

Dafoe-Lambie JD, Abel LJ, Blatt HJ, Fuscardo JA, Stipetich RL, Lief JH, Dorsey AT, Butler WM, Benson ML, Merrick GS. Radioactive Seed Embolization to the Lung Following Prostate Brachytherapy. WV Med J 2000; 96:357-360.

 

Merrick GS, Butler WM, Lief JH, Dorsey AT. Temporal Resolution of Urinary Morbidity Following Prostate Brachytherapy. Int J Radiat Onc Biol Phys 2000; 47:121-128.

 

Abel LJ, Blatt H, Stipetich RL, Fuscardo JA, Dafoe-Lambie JC, Dorsey AT, Butler WM , Merrick GS. The Role of Urinary Assessment Scores in the Nursing Management of Patients Receiving Prostate Brachytherapy. Clin J Oncol Nursing 2000; 4:126-129.

 

Butler WM, Merrick GS, Dorsey AT, Lief JH. Isotope Choice and the Effect of Edema on Prostate Brachytherapy Dosimetry. Med Phys 2000; 27:1067-1075.

 

Beyer D, Nath R, Butler W, Merrick G, Blasko J, Nag S, Orton C. American Brachytherapy Society Recommendations for Clinical Implementation of NIST-1999 Standards for 103Palladium Brachytherapy. Int J Radiat Onc Biol Phys 2000; 47:273-275.

 

Merrick GS, Butler WM, Dorsey AT, Lief JH, Totterdale MC, Coram RJ. The Influence of Prophylactic Dexamethasone on Edema Following Prostate Brachytherapy. Tech Urol 2000; 6:117-122.

Merrick GS, Butler WM. Modified Uniform Seed Loading for Prostate Brachytherapy: Rationale, Design and Evaluation. Tech Urol 2000; 6:78-84.

 

Rich TA, Ota D, Rosenthal SA, Minsky BD, Bader JL, Coia LR, Janjan NA, John MJ, Merrick GS, Raben D, Tepper JE, Saltz L, Leibel S for the Expert Panel on Radiation Oncology-Rectal/Anal Cancer Work Group. Management of Resectable Rectal Cancer. Radiology 2000; 215 (S):1473-1480.

 

Tepper JE, Bader JL, Janjan NA, Minsky BD, Coia LR, John MJ,  Merrick GS,  Raben D, Rich TA, Rosenthal SA, Ota D, Saltz L, Leibel S for the Expert Panel on Radiation Oncology-Rectal/Anal Cancer Work Group. Locally Unresectable Rectal Cancer. Radiology 2000; 215 (S):1481-1490.

 

Saltz L, Raben D, Minsky BD, Bader JL, Coia LR, Janjan NA, John MJ, Merrick GS, Rich TA, Rosenthal SA, Tepper JE, Ota D, Leibel S for the Expert Panel on Radiation Oncology-Rectal/Anal Cancer Work Group. Rectal Cancer: Presentation with Metastatic and Locally Advanced Disease. Radiology 2000; 215 (S):1491-1499.

 

John MJ, Merrick GS, Coia LR, Minsky BD, Bader JL, Janjan NA, Raben D, Rich TA, Rosenthal SA,  Tepper JE, Ota D, Saltz L, Leibel S for the Expert Panel on Radiation Oncology-Rectal/Anal Cancer Work Group. Anal Cancer. Radiology 2000; 215(S):1501-1511.

 

Merrick GS, Butler WM, Dorsey AT, Galbreath RW, Blatt H, Lief JH. Rectal Function Following Prostate Brachytherapy. Int J Radiat Onc Biol Phys 2000; 48(3):667-674.

 

Butler WM, Merrick GS, Dorsey AT, Lief JH, Galbreath RW. Modern Prostate Brachytherapy. Med Dosm 2000; 25:149-153.

Merrick GS, Butler WM, Dorsey AT, Dorsey JT. The Effect of Constipation on Rectal Dosimetry Following Prostate Brachytherapy. Med Dosm 2000; 25:237-241.

 

Merrick GS, Butler WM, Dorsey AT, Lief JH, Donzella JG. A comparison of radiation dose to the neurovascular bundles in men with and without prostate brachytherapy induced erectile dysfunction. Int J Radiat Onc Biol Phys 2000; 48:1069-1074.

Butler WM, Merrick GS, Dorsey AT, Hagedorn BM. Comparison of dose length, area and volume histograms as quantifiers of urethral dose in prostate brachytherapy. Int J Radiat Onc Biol Phys 2000; 48:1575-1582.

 

Donzella JG, Merrick GS. PSA utility: an overview article. Student Doctor 2000; 21:38-41.

 

Wallner K, Merrick G, True L, Kattan M, Cavanagh W, Simpson C, Butler W. I-125 versus Pd-103 for low risk prostate cancer: Preliminary urinary functional outcomes from a prospective randomized trial. J Brachy Int 2000; 16:151-155.

 

Merrick GS, Butler WM, Lief JH, Dorsey AT. Is Brachytherapy Comparable with Radical Prostatectomy and External Beam Radiation for Clinically Localized Prostate Cancer? Tech Urol, 2001; 7:12-19.

 

Merrick GS, Butler WM, Galbreath RW, Lief JH, Donzella JG. The relationship between the transition zone index of the prostate gland and urinary morbidity following brachytherapy. Urol 2001; 57:524-529.

 

Merrick GS, Wallner K, Butler WM, Galbreath RW, Lief JH, Benson ML. A comparison of radiation dose to the bulb of the penis in men  with and without prostate brachytherapy induced erectile dysfunction. Int J Radiat Oncol Biol Phys 2001; 50:597-604.

 

Merrick, GS, Butler WM, Lief JH, and Galbreath RW. Five year biochemical outcome after prostate brachytherapy for hormone naive men ≤ 62 years of age. Int J Radiat Oncol Biol Phys 2001; 50:1253-1257.

Merrick GS, Butler WM, Lief JH, and Galbreath RW. Five year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer. Int J Radiat Oncol Biol Phys 2001; 51:41-48.

 

Merrick GS, Wallner K, Butler WM, Lief JH,  Sutlief S. Short-term sexual function after prostate brachytherapy. Int J Cancer (Radiat Oncol Invest) 2001; 96:313-319.

Merrick GS, Butler WM, Dorsey AT, Lief JH, Bhullar S. The Effect of Prostate Size and Isotope Selection on Dosimetric Quality Following Permanent Seed Implantation. Tech Urol 2001; 7:233-240.

 

Blatt HJ, Abel LJ, Stipetich RL, Galbreath RW, Lief JH, Butler WM, Merrick GS. Utilization of a Self-Administered Questionnaire to Assess Rectal Function Following Prostate Brachytherapy. Urologic Nursing 2001; 21:356-359.

 

Merrick GS, Butler WM, Lief JH, Galbreath RW, and Adamovich E. Perineural invasion is not predictive of biochemical outcome following prostate brachytherapy. Cancer J 2001; 7:404-412.

 

Merrick GS, Butler WM, Lief JH, Galbreath RW. Permanent prostate brachytherapy: Do prostatectomy and external beam measure up? J Brachy Int 2001; 17:189-204.

 

Merrick GS, Butler WM, Lief JH, Galbreath RW. Permanent prostate brachytherapy: Acute and late toxicities. J Brachyther Int 2001; 17:229-236.

Merrick GS, Butler WM, Tollenaar BG, Galbreath RW, Lief JH. The dosimetry of prostate brachytherapy-induced urethral strictures. Int J Radiat Oncol Biol Phys 2002; 52:461-468.

 

Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E. Biochemical outcome of patients with Gleason score 3+4 versus 4+3 prostate cancer undergoing permanent prostate brachytherapy. Urology 2002; 60:98-103.

 

Merrick GS, Butler WM, Lief JH, Galbreath RW, Adamovich E. Biochemical outcome for hormone naive patients with intermediate risk prostate cancer managed with permanent interstitial brachytherapy. Brachytherapy 2002; 1:95-101.

 

Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E. The relationship between percent positive biopsies and biochemical outcome following permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland. Int J Radiat Oncol Biol Phys 2002; 52:664-673.

Merrick GS, Butler WM, Galbreath RW, Stipetich RL, Abel LJ, Lief JH. Erectile function after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002; 52:893-902. 

 

Hughes S, Wallner KE, Merrick GS, Butler WM, Miller SE, True LD. Pre-existing histologic evidence of prostatitis is unrelated to post-implant urinary morbidity. Radiat Oncol Invest 2002; 96 (Suppl):79-82.                                                                        

 

Wallner K, Merrick G, True L, Kattan MW, Cavanagh W, Simpson  C, and Butler W. I-125 versus Pd-103 for low risk prostate cancer: Morbidity outcomes from a prospective randomized multicenter trial. Cancer J 2002; 8:67-73.                                             

 

Jones S, Wallner K, Merrick G, Corriveau J, Sutlief S, True L, and Butler W. Clinical correlates of high intraprostatic brachytherapy dose regions. Int J Radiat Oncol Biol Phys 2002; 3:328-333.

 

Merrick GS, Butler WM, Lief JH, Galbreath RW, Adamovich E. Biochemical outcome for hormone naive patients with high risk prostate cancer managed with permanent interstitial brachytherapy. Cancer J 2002; 8:322-327.

 

Rockhill J, Wallner K, Hoffman C, Merrick G, Simpson C, Arthur S. Prostate brachytherapy in obese patients. Brachytherapy 2002; 1:54-60.

 

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL, Kurko BS, Lief JH. Permanent prostate brachytherapy-induced morbidity in patients with grade II and III obesity. Urology 2002; 60:104-108.

 

Wallner KE, Merrick GS, Benson ML, Butler WM, Maki J, and Tollenaar BG. Penile bulb imaging. Int J Radiat Oncol Biol Phys 2002; 53:928-933.

 

Stipetich RL, Abel LJ, Blatt HJ, Galbreath RW, Lief JH, Butler WM, and Merrick GS. Nursing assessment of sexual function following permanent prostate brachytherapy for patients with early stage prostate cancer. Clin J Oncol Nursing 2002; 6:271-274.

Nag S, Ellis RJ, Merrick GS, Bahnson R, Vicini F, Wallner K, Stock R, Lee R. American Brachytherapy Society Recommendations for Reporting Morbidity After Prostate Brachytherapy. Int J Radiat Oncol Biol Phys 2002; 54:462-470.

 

Mueller A, Wallner K, Merrick G, Corriveau J, Sutlief S, Butler W, Gong L, and Cho P. Modification of prostate implants based on post-implant treatment margin assessment. Med Phys 2002; 29:2782-2787.

 

Merrick GS, Butler WM, Wallner KE, Lief JH, Galbreath RW. Prophylactic versus therapeutic alpha blockers following permanent prostate brachytherapy. Urology 2002; 60:650-655.

 

Merrick GS, Butler WM, Wallner KE, Galbreath RW, and Anderson RL. Prostate specific antigen (PSA) spikes following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002; 54:450-456.

 

Merrick GS, Butler WM, Wallner KE, Lief JH, Anderson RL, Smeiles BJ, Galbreath RW, Benson ML. The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction. Int J Radiat Oncol Biol Phys 2002; 54:1055-1062.

 

Merrick GS, Butler WM, Wallner KE, Burden LR, Dougherty JE. Extracapsular radiation dose distribution following permanent prostate brachytherapy. Am J Clin Oncol 2003; 26:E178-E189.

 

Barker J, Wallner K, and Merrick G. Hematuria after prostate brachytherapy. Urology 2003; 61:408-411.

 

Merrick GS, Wallner KE, Butler WM. Management of sexual dysfunction after prostate brachytherapy. Oncology 2003; 17:52-61.

 

Smith S, Wallner K, Merrick G, Gong L, Cho P, Sutlief S, Butler W, Grimm P. Interpretation of pre- versus postimplant TRUS images. Med Phys 2003; 30:920-924.

 

Merrick GS, Wallner KE, Butler WM. Permanent interstitial brachytherapy in the management of carcinoma of the prostate gland (review article). J Urol 2003; 169:1643-1652.

 

Butler WM, Merrick GS. Myths and fallacies in permanent prostate brachytherapy. Med Dosm 2003; 28:155-165.

 

Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E. Does hormonal manipulation in conjunction with permanent interstitial brachytherapy with or without supplemental external beam improve biochemical outcome for intermediate or high risk prostate cancer? British J Urol 2003; 91:23-29.

 

Abel L, Dafoe-Lambie J, Butler WM, Merrick GS. Treatment outcomes and quality of life issues for patients treated with prostate brachytherapy. Clin J Oncol Nurs 2003; 7:48-54.

 

Ghaly M, Wallner K, Merrick G, True L, Sutlief S, Cavanagh W, and Butler W. Brachytherapy versus brachytherapy plus beam radiation for prostate cancer: Morbidity outcomes from two prospective randomized multicenter trials. Int J Radiat Oncol Biol Phys 2003; 55:1288-1293.

 

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Murray B, Zeroski D, Lief JH. Dysuria following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003; 55:979-985.

 

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH. Long-term urinary quality of life following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003; 56:454-461.

Merrick GS and Butler WM. The dosimetry of brachytherapy-induced erectile dysfunction. Med Dosm 2003; 28:271-274.

 

Han B, Wallner K, Merrick G, Butler W, Sutlief S, and Sylvester J. Prostate brachytherapy seed identification on post-implant TRUS images. Med Phys 2003; 30:898-900.

 

Han BH, Wallner K, Merrick G, Badiozamani K, and Butler W. The effect of inter-observer differences in post-implant prostate CT image interpretation on dosimetric parameters. Med Phys 2003; 30:1096-1102.

Reed D, Wallner KE, Merrick G, Butler W, Han BH, Sutlief SG, and Cho PS. Post-implant isodose patterns in patients with inadequate prostate brachytherapy coverage. Int J Radiat Oncol Biol Phys 2003; 56:1480-1487.

 

Reed D, Wallner K, Merrick G, Buskirk S, and True L. Clinical correlates to PSA spikes and positive repeat biopsies after prostate brachytherapy. Urology 2003; 62:683-688.

 

Merrick GS, Wallner KE, Butler WM. Minimizing prostate brachytherapy-related morbidity (review article). Urology 2003; 62:786-792.

 

Merrick GS, Butler WM, Wallner KE, Lief JH, Mulroy A, Galbreath RW. Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy. Brachytherapy 2003; 2:181-188.

 

Merrick GS, Wallner KE, Butler WM, Galbreath RW, Kurko B, Cleavinger S. Rectal function following brachytherapy with or without supplemental external beam radiation: Results of 2 prospective randomized trials. Brachytherapy 2003; 2:147-157.

 

Merrick GS, Wallner KE, Butler WM, Hines AL, Allen Z. Late rectal function following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003; 57:42-48.

 

Wallner K, Merrick G, True L, Sutlief S, Cavanagh W, Butler W. I-125 versus Pd-103 for low risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial. Int J Radiat Oncol Biol Phys 2003; 57:1297-1303.

 

Corriveau J, Wallner K, Merrick G, True L, Cavanagh W, Sutlief S, and Butler W. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy. Brachytherapy 2003; 2:108-113.

Merrick GS and Butler WM. Rectal function following permanent prostate brachytherapy. West Virginia State Medical Journal 2004; 100:18-20.


Hoffelt C, Wallner K, Merrick G. Epididymitis following prostate brachytherapy. Urology 2004; 63:293-296.

 

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Adamovich E. Permanent interstitial brachytherapy for clinically organ-confined high-grade prostate cancer with a pretreatment PSA < 20 ng/mL. Am J Clin Oncol 2004; 27:611-615.

 

Merrick GS, Butler WM, Wallner KE, Galbreath RW. The effect of transurethral resection on urinary quality of life following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004; 58:81-88.

 

Merrick GS, Butler WM, Wallner KE, Murray B, Allen Z, Lief JH, Galbreath RW. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy. Brachytherapy 2004; 3:22-29.

 

Merrick GS, Butler WM, Wallner KE, Anderson RL, Galbreath RW, Lief JH, Adamovich E. Effect of cigarette smoking on biochemical outcome following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004; 58:1056-1062.

 

Merrick GS, Butler WM, Wallner KE, Murray BC, Allen Z, Galbreath RW. The influence of hormonal therapy on late rectal function following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004; 58:68-74.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Adamovich E. Prognostic significance of percent positive biopsies in clinically organ-confined prostate cancer treated with permanent prostate brachytherapy with or without supplemental external beam radiation. The Cancer Journal 2004; 10:54-60.

 

Donzella JG, Merrick GS, Lindert DJ, Andreini HJ Jr., Curtis RL, Luna IH, Allen ZA, Butler WM. Epididymitis following transrectal ultrasound-guided needle biopsy of the prostate gland. Urology 2004; 63:306-308.

 

Elliott K, Wallner K, Merrick G, Herstein P. Medical malpractice of prostate brachytherapy. Brachytherapy 2004; 3:231-236.


Merrick GS, Wallner KE, Butler WM. Patient selection for prostate brachytherapy: More myth than fact. Oncology 2004; 18:445-452.

 

Merrick GS, Wallner KE, Butler WM, Galbreath RW. Permanent interstitial brachytherapy for younger patients with clinically organ-confined prostate cancer. Urology 2004; 64:754-759.

 

Mueller A, Wallner K, Merrick G, Cavanagh W, Butler WM. Peri-rectal seeds as a risk factor for prostate brachytherapy-related rectal bleeding. Int J Radiat Oncol Biol Phys 2004; 59:1047-1052.

Choi ST, Wallner K, Merrick G, Cavanagh W, and Butler W. Treatment margins predict biochemical outcomes after prostate brachytherapy. Cancer J Sci Am 2004; 10:175-180.

 

Hinerman-Mulroy A, Merrick GS, Butler WM, Wallner KE, Allen ZA, Adamovich A. Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity following permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2004; 59:1367-1382.

 

Merrick GS, Butler WM, Wallner KE, Allen ZA, Lief JH, Hinerman-Mulroy A, Galbreath RW. The impact of prostate volume and neoadjuvant androgen deprivation therapy on urinary function following prostate brachytherapy. Cancer J 2004; 10:181-189.

 

Sherertz T, Wallner K, Merrick G, Cavanagh W, Butler W, and True L. Factors predictive of rectal bleeding after (103)Pd and supplemental beam radiation for prostate cancer. Brachytherapy 2004; 3:130-135.

 

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E. Temporal effect of neoadjuvant androgen deprivation therapy on PSA kinetics following permanent prostate brachytherapy with or without supplemental external beam radiation. Brachytherapy 2004; 3:141-146.

 

Wallner K, Elliot K, Merrick G, Ghaly M, and Maki J. Chronic pelvic pain following prostate brachytherapy: A case report. Brachytherapy 2004; 3:153-158.

Sherertz T, Wallner K, Merrick G, Cavanagh W, Butler W, Reed D, and True L. The prognostic significance of Gleason pattern 5 cancer in prostate cancer patients treated with Pd-103 plus beam radiation. Cancer J 2004; 10:301-306.

 

Merrick GS, Butler WM, Wallner KE. Patient selection for prostate brachytherapy. Business Briefing: US Oncology Review 2004; 68-70.

Reed DR, Wallner K, Ford E, Mueller A, Merrick G, Maki J, Sutlief S, and Butler W. Effect of post-implant edema on prostate brachytherapy treatment margins. Int J Radiat Oncol Biol Phys 2005; 63:1469-1473.

 

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Lief JH, Adamovich E. The influence of body mass index (BMI) on biochemical outcome following permanent prostate brachytherapy. Urology 2005; 65:95-100.

 

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Allen ZA, Adamovich E. The impact of supplemental external beam radiation and/or androgen deprivation therapy on biochemical outcome following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005; 61:32-43.

Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW, Lief JH. Brachytherapy-related dysuria. BJU Int 2005; 95:597-602.

 

Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW, Lief JH. The impact of radiation dose to the urethra and brachytherapy-related dysuria. Brachytherapy 2005; 4:45-50.

 

Wallner K, Merrick G, Sutlief S, True L, Butler W. High-dose regions versus likelihood of cure after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005; 62:170-174.

 

Merrick GS, Butler WM, Wallner, Galbreath RW, Anderson RL, Kurko BC, Lief JH, Allen ZA. Erectile function following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005; 62:437-447.

 

Merrick GS, Wallner KE, and Butler WM. Prostate cryotherapy: More Questions than Answers. Urology 2005; 66:9-15.

 

Merrick GS, Butler WM, Wallner KE, Allen Z, DeFilippo JL, Adamovich E. The role of enzymatic prostatic acid phosphatase in the clinical staging evaluation of patients with newly diagnosed, untreated prostate cancer. West Virginia Medical Journal 2005; 101:116-119.


Allen ZA, Merrick GS, Butler WM, Wallner KE, Kurko B, Anderson RL, Murray BC, Galbreath RW. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity. Int J Radiat Oncol Biol Phys 2005; 62:981-987.

Zeroski DJ, Abel LJ, Stipetich RL, Merrick GS. Factors affecting patient selection for prostate brachytherapy. Clin J Oncol Nurs 2005; 9:553-574.

 

Stipetich RL, Abel LJ, Anderson RL, Butler WM, Wallner KE, Merrick GS. Nursing considerations in brachytherapy-related erectile dysfunction. Urologic Nursing 2005; 25:249-254.

 

Merrick GS, Butler WM, Wallner KE, Blasko JC, Michalski J, Aronowitz J, Grimm PD, Moran BJ, McLaughlin WP, Usher J, Lief JH, Allen ZA. Variability of prostate brachytherapy preimplant dosimetry: A multi-institutional analysis. Brachytherapy 2005; 4:241-251.

 

Merrick GS, Butler WM, Wallner KE. Brachytherapy-associated erectile dysfunction. Current Sexual Health Reports 2005; 2:21-26.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E. The impact of primary Gleason grade on biochemical outcome following brachytherapy for Gleason score 7 prostate cancer. Cancer J 2005; 11:234-240.

 

Wright J, Wallner K, Merrick G, Prestidge B, and Dominitz J. Rectal fistulas following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005; 63:150-154.

 

Moyad MA and Merrick GS. Statins and cholesterol lowering after a cancer diagnosis: Why not?  Urologic Oncology 2005; 23:49-55.

 

Wallner KE, Merrick G, True L, Sherertz T, Sutlief S, Cavanagh W, Butler W. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: Early biochemical outcomes from a prospective randomized multicenter trial. Radiotherapy and Oncology 2005; 75:307-310.

 

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Adamovich E. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer. WV Medical Journal 2005; 101:168-171.

Nedea E, Wallner K, Reed D, Ford E, Sutlief S, Mueller A, Maki J, Merrick G. Extraprostatic seed placement and its effect on seed loss. Cancer J 2005; 11:147-151.

 

Herstein A, Wallner K, Merrick G, Armstrong J, True L, Cavanagh W, and Butler W. I-125 versus Pd-103 for low risk prostate cancer: Morbidity outcomes from a prospective randomized multi-center controlled trial. Cancer J 2005; 11:385-389.

Beekman M, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW. Selecting patients with a pretreatment post-void residual urine < 100 cc may favorably influence brachytherapy-related urinary morbidity. Urology 2005; 66:1266-1270.

 

Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Kurko BC, Adamovich E. Statins, especially atorvastatin, may favorably influence clinical presentation and biochemical progression-free survival following brachytherapy for clinically localized prostate cancer. Urology 2005; 66:1150-1154.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E. Prognostic significance of perineural invasion following prostate brachytherapy. Urology 2005; 66:1048-1053.

Moyad MA and Merrick GS. Statins, cholesterol, and prostate cancer: Looking at the forest, not the trees. Am J Urol Rev 2005; 3:514-518.

Tran A, Wallner K, Merrick G, Seeberger J, Armstrong J, Mueller A, Cavanagh W, Lin D, Butler W. Rectal fistulas after prostate brachytherapy. Int J Radiat Oncol Biol Phys 2005; 63:150-154.

 

Reed DR, Wallner K, Ford E, Muller A, Merrick G, Sutlief S, Butler W. Effect of post-implant edema on prostate brachytherapy treatment margins. Int J Radiat Oncol Biol Phys 2005; 63(5):1469-73.

 

Niehaus A, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW, Adamovich A. The influence of isotope and prostate volume on urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006; 64:136-143.

 

Gutman S, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW. Severity categories of the International Prostate Symptom Score before, and urinary morbidity after, permanent prostate brachytherapy. BJU Int 2006; 97:62-68.

 

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL, Allen, ZA, Adamovich E. Risk Factors for the Development of Prostate Brachytherapy Related Urethral Strictures. J Urol, 2006; 175:1376-1381.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Kurko BS. Efficacy of neoadjuvant bicalutamide and dutasteride as a cytoreductive regimen prior to prostate brachytherapy. Urology 2006; 68:116-120.

 

Merrick GS, Wallner KE, Butler WM, Blasko JC. Permanent prostate brachytherapy: Is supplemental external beam radiation therapy necessary? Oncology 2006; 20:514-522.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich A. Androgen deprivation therapy does not impact cause-specific or overall survival following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006; 65:669-677.

 

Gutman S, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath RW, Adamovich E. Temporal relationship between prostate brachytherapy and the diagnosis of colorectal cancer. Int J Radiat Oncol Biol Phys 2006; 66(1):48-55.

 

Merrick GS, Wallner KE, Butler WM, Galbreath RW, Allen ZA, Adamovich E, True L. Brachytherapy in men ≤ 54 years of age with clinically localized prostate cancer. BJU Int 2006; 98:324-328.

 

Moyad MA, Merrick GS. Cholesterol, Cholesterol Lowering Agents/Statins, and Urologic Disease: Part 1 – Knowing Your Number. Urol Nurs 2006; 26: 156-159.

Moyad MA, Merrick GS. Cholesterol, Cholesterol Lowering Agents/Statins, and Urologic Disease: Part II – do you know your Framington Risk Score? Urol Nurs 2006; 26(3):227-229,203.

Moyad MA, Merrick GS. Cholesterol, Cholesterol-Lowering Agents/Statins, and Urologic Disease: Part III – A Rapid Review of FDA-Approved Cholesterol-Lowering Agents. Urol Nurs 2006; 26(4): 330-332.

Moyad MA, Merrick GS. Cholesterol, Cholesterol Lowering Agents/Statins, and Urologic Disease: Part IV - is vitamin E phosphate or another unique type of this vitamin the last chance for these supplements? Urol Nurs 2006; 26(5):415-418.

Moyad MA, Merrick GS, Butler WM, Wallner KE, Galbreath RW, Butler EG, Allen ZA, Adamovich A. Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer. Urol Nurs 2006; 26(4):298-303.

Mitsuyama H, Wallner KE, Merrick GS. Treatment of Prostate Cancer in Obese Patients. Oncol 2006; 20:1191-1208.

 

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Anderson RL, Allen ZA. Prostate brachytherapy-induced urethral strictures. J Urol 2006; 175:1376-1380.

 

Mitsuyama P, Wallner K, Merrick GS. Treatment of prostate cancer in obese patients. Oncol 2006; 20:1191-1197.

Sylvester JE, Grimm PD, Blasko JC, Millar J, Orio PF, Skoglund S, Galbreath RW, Merrick G. 15-year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. Int J Radiat Oncol Biol 2007; 67:57-64.

 

Orio P, Wallner K, Merrick G, Herstein A, Mitsuyama P, Thornton K, Butler W, Sutlief S. Dosimetric parameters as predictive factors for biochemical control in patients with higher risk prostate cancer treated with Pd-103 and supplemental beam radiation. Int J Radiat Oncol Biol 2007; 67:342-346.

Rivard MJ, Butler WM, Devlin PM, Hayes, Jr JK, Hearn RA, Lief EP, Meigooni AS, Merrick GS, Williamson JF. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. Brachytherapy 2007; 6:34-37.

Frank SJ, Blasko JC, Sylvester JE, Kuban DA, Moran BJ, Wallner KE, Vera R, Merrick GS, Zietman AL, Roach M, Clark D, Prestidge BR, Potters L, Michalski JM, Beyer DC, Lee WR, Stock RG, Davis BJ, Hurwitz MD, Grimm PD. Interstitial implant alone with or without external beam radiation therapy for intermediate risk localized prostate cancer: Patterns of Care Study in the United States. Brachytherapy 2007; 6:2-8.

Merrick GS, Grimm PD, Sylvester J, Blasko J, Butler WM, Allen ZA, Chaudhry U, Mazza A, Sitter M. Initial analysis of Pro-Qura, a multi-institutional database of prostate brachytherapy dosimetry. Brachytherapy 2007; 6:9-15.

Reed D, Wallner KE, Merrick GS, Arthurs S, Mueller A, Cavanagh W, Butler WM, Ford E, Sutlief S. A prospective randomized comparison of stranded vs. loose 125I seeds for prostate brachytherapy. Brachytherapy 2007; 6:129-134.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E. Androgen deprivation therapy does not impact cause-specific or overall survival in high risk prostate cancer managed with brachytherapy and supplemental external beam. Int J Radiat Oncol Biol Phys 2007; 68(1):34-40.

Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Gutman S, Lief J. Long-term rectal function following permanent prostate brachytherapy. Cancer J 2007; 13(2):95-104.

Galbreath RW, Gutman S, Merrick GS, Nwsou K, Allen ZA, Butler WM. Appropriate exercise training benefits men receiving androgen deprivation therapy. Sem in Prev Alt Med 2007; 2(4):208-211.

Merrick GS, Butler WM, Wallner KE, Allen ZA, Kurko BC, Anderson RL, Grammer R, Galbreath RW. Dosimetry of an extracapsular annulus following permanent prostate brachytherapy. Am J Clin Oncol 2007; 30(3):228-233.

Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, Lief J, Adamovich E. Primary Gleason pattern does not impact survival following permanent interstitial brachytherapy for Gleason score 7 prostate cancer. Cancer 2007; 110:289-296.

Moyad MA, Merrick GS. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part V – Statins versus aspirin for primary prevention, and the winner is … ? Urol Nurs 2007; 27(2):166-168.

Moyad MA, Merrick GS. Cholesterol, cholesterol-lowering agents/statins, and urologic disease: Part VI – The recent rise and fall of the HDL-boosting drug torceptrapib. Urol Nurs 2007; 27(2):169-173.

Bostancic C, Merrick GS, Butler WM, Wallner KE, Allen ZA, Galbreath R, Lief J, Gutman S. Isotope and patient age predict for PSA spikes following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2007; 68(5):1431-1437.

Merrick GS, Gutman S, Andreini H, Taubenslag W, Lindert D, Curtis R, Adamovich E, Anderson R, Allen Z, Butler W, Wallner K. Prostate cancer distribution in patients diagnosed by transperineal template-guided saturation biopsy. European Urology 2007; 52:715-724.

Orio P, Tutar I, Narayanan S, Arthurs S, Cho P, Kim Y, Merrick G, Wallner K. Intra-operative TRUS/fluoro fusion improves prostate brachytherapy quality. Int J Radiat Oncol Biol Phys 2007; 69(1):302-307.

Taira A, Merrick G, Wallner K, Dattoli M. Reviving the acid phosphatase test for prostate cancer. Oncology 2007; 21(8):1003-10.

Merrick GS, Butler WM, Wallner KE. Radiation thresholds and rehabilitative therapy with erectile preservation after radiotherapy for prostate cancer. Current Sexual Health Reports 2007; 4:109-113.

Taira A, Merrick G, Wallner K, Dattoli M. Reviving the acid phosphatase test for prostate cancer. Oncology 2007; 21(8):1003-10.

Brammer S, Merrick GS, Galbreath R, Butler W, Nwsou K, Allen ZA. Penile rehabilitative therapy following brachytherapy for early stage prostate cancer. Seminars in Preventive and Alternative Medicine 2007; 3:14-17.

Nurani RD, Wallner KE, Merrick GS, Virgin J, Orio P, True L. Optimized prostate brachytherapy minimizes the prognostic impact of percentage of biopsy cores involved with adenocarcinoma. J Urol 2007; 178(5):1968-1973.

Bittner N, Merrick GS, Wallner K, Lief J, Butler W, Galbreath R. The impact of acute urinary morbidity on late urinary function following permanent prostate brachytherapy. Brachytherapy 2007; 6(4):258-266.

Abel L, Zeroski D, Gutman S, Butler W, Wallner K, Merrick G. PSA spike after brachytherapy for localized prostate cancer. Urologic Nursing 2007; 27(6):507-518.

Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, Adamovich E. Obesity is not predictive of overall survival following permanent prostate brachytherapy. Am J Clin Oncol 2007; 30(6):588-596.

Mitsuyama P, Wallner K, Merrick GS, Virgin J, Orio P, Montgomery B, True L. The prognostic significance of Gleason pattern 5 in prostate cancer patients treated with Pd-103 brachytherapy. Am J Clin Oncol 2007; 30(6):597-600.

Herstein A, Wallner K, Merrick GS, Orio P, Thornton K, Butler W, Sutlief S. There is a wide range of predictive dosimetric factors for I-125 and Pd-103 prostate brachytherapy. Am J Clin Oncol 2007; 31(1):6-10.

Bittner N, Merrick GS, Brammer S, Niehaus A, Wallner KE, Butler WM, Allen ZA, Galbreath R. Role of Trospium Chloride in brachytherapy-related detrusor overactivity. Urology 2008; 71:460-464.

Butler WM, Merrick GM. Clinical Practice and Quality Assurance Challenges in Modern Brachytherapy Sources and Dosimetry. Int J Radiat Oncol Biol Phys 2008; 71:S142-S146.

Butler WM, Merrick GM. Clinical Practice and Quality Assurance Challenges in Modern Brachytherapy Sources and Dosimetry. Int J Radiat Oncol Biol Phys 2008; 71:S142-S146.

Bittner N, Wallner K, Merrick G, Orio P, Nurani R, True L, Butler W. The time gap between Pd-103 prostate brachytherapy and supplemental beam radiation does not impact on rectal morbidity or likelihood of cure. Am J Clin Oncol 2008; 31:231-236.

Moyad MA, Merrick GS. Statins, diet, and dietary supplements for prostate cancer: A potential connection and recommendation based on probability. Semin Prev Altern Med 2008; 3:140-146.

Allen Z, Merrick GS, Grimm P, Blasko J, Sylveser J, Butler W, Chaudry U, Sitter M. Influence of pro-qura generated plans on post-implant dosimetric quality: a review of a multi-institutional database. Med Dos 2008; 33(3):206-214.

Bittner N, Merrick GS, Wallner KE, Butler W. Interstitial brachytherapy should be standard of care for treatment of high risk prostate cancer. Oncology 2008; 22(9):995-1004.

Aronowitz JN, Crook JM, Michalski JM, Sylvester JE, Merrick GS, Mawson C, Pratt D, Naidoo D, Butler WM, Karolczuk K. Interinstitutional variation of implant activity for permanent prostate brachytherapy. Brachytherapy 2008; 7:297-300.

Bittner N, Merrick GS, Galbreath RW, Butler WM, Wallner KE, Allen ZA, Brammer SG, Moyad M. Primary causes of death after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2008; 72:443-440.

Merrick GS, Wallner KE, Galbreath RW, Butler WM, Brammer SG, Allen ZA, Lief JH, Adamovich E. Biochemical and functional outcomes following brachytherapy in men ≤ 50 years of age with clinically organ-confined prostate cancer. Am J Clin Oncol 2008; 31:539-544.

Merrick G, Wallner K, Galbreath R, Butler W, Brammer S, Allen Z, Adamovich E. Prostate brachytherapy in men > 75 years of age. Int J Radiat Oncol Biol Phys 2008; 72:415-420.

Fang LC, Merrick GS, Wallner KE. Androgen deprivation therapy: a help or hindrance for survival in high-risk prostate cancer? US Oncology 2008; 55-59.

Orio PF, Merrick GS, Grimm P, Blasko J, Sylvester J, Allen Z, Butler W, Chaudhry U. Effects of the time interval between prostate brachytherapy and post-implant dosimetric evaluation in community practice: analysis of the pro-qura database. Am J Clin Oncol 2008; 31:523-531.

Butler WM, Stewart RR, Merrick GS. A detailed radiobiological and dosimetric analysis of biochemical outcomes in a case control study of permanent prostate brachytherapy patients. Med Phys 2009; 36:776-787.

Everly L, Merrick GS, Allen ZA, Butler WM, Wallner KE, Lief JH, Galbreath RW, Adamovich E. Prostate cancer control and survival in Vietnam Veterans exposed to Agent Orange. Brachytherapy 2009; 8:57-62.

Loiselle CR, Waheed M, Sylvester J, Allen ZA, Grimm PD, Eulau S, Butler WM, Merrick GS. Analysis of the Pro-Qura database: rectal dose, implant quality, and brachytherapist experience. Brachytherapy 2009; 8:34-39.

Michalski JM, Roach M, Merrick GS, Anscher MS, Beyer DC, Lawton CA, Lee WR, Pollack A, Rosenthal SA, Vijayakumar S, Carroll PR. ACR Appropriateness Criteria (R) on external beam radiation therapy treatment planning for clinically localized prostate cancer expert panel on radiation oncology prostate. Int J Radiat Oncol Biol Phys 2009; 74:667-672.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Allen ZA, Lief JH, Adamovich E. Pretreatment Serum testosterone and androgen deprivation: effect on disease recurrence and overall survival in prostate cancer patients treated with brachytherapy. Int J Radiat Oncol Biol Phys 2009; 74:1143-1149.

Orio PF, Merrick GS, Allen ZA, Butler WM, Wallner KE, Kurko BS, Galbreath RW. External beam radiation results in minimal changes in post void residual urine volumes during the treatment of clinically localized prostate cancer. Radiation Oncology 2009; 4:26.

Bittner N, Merrick GS, Andreini H, Taubenslag W, Allen ZA, Butler WM, Anderson RL, Adamovich E, Wallner KE. Pre-biopsy prostate specific antigen velocity is not a reliable predictor of prostate cancer diagnosis, Gleason score, tumor location, or cancer volume following transperineal template-guided prostate mapping biopsy. Urology 2009; 74:171-176.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Wallner KE, Kurko BS, Anderson R, Lief JH. Erectile function durability following permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009; 75:639-649.

Taira AV, Merrick GS, Galbreath RW, Wallner KE, Butler WM. Natural history of clinically-staged low and intermediate risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2009; 76:349-354.

Waheed M, Alahmar A, Allen ZA, Marks R, Butler WM, Wallner KE, Merrick GS. Adolescent awareness of testicular self examination and testicular cancer. WV Med Journal 2009; 105:22-28.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Wallner KE. Factors impacting all-cause mortality in prostate cancer brachytherapy patients with or without anrogen deprivation therapy. Brachytherapy 2010; 9:42-49.

Taira AV, Merrick GS, Galbreath RW, Andreini H, Taubenslag W, Curtis R, Butler WM, Adamovich E, Wallner KE. Performance of transperineal template guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting. Prostate Cancer and Prostatic Diseases 2010; 13:71-77.

Bittner N, Merrick GS, Wallner KE, Butler WM, Galbreath R, Adamovich E. Whole pelvic radiotherapy in combination with interstitial brachytherapy: Does coverage of the pelvic lymph nodes improve treatment outcome in high-risk prostate cancer? Int J Radiat Oncol Biol Phys 2010; 76:1078-1084.

Mayadev J, Merrick GS, Reed J, Butler WM, Galbreath RW, Allen ZA, Wallner KE. Permanent prostate brachytherapy in prostate glands < 20 cm3. Int J Radiat Oncol Biol Phys 2010; 76:1450-1455.

King BL, Butler WM, Merrick GS, Kurko BS, Reed JL, Murray BC. Electromagnetic transponders indicate prostate size increase then decrease during the course of external beam radiation therapy. Int J Radiat Oncol Biol Phys 2010; 77:490-495.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Lief JH, Wallner KE. Relationship between prostate cancer mortality and number of unfavourable risk factors in men treated with definitive brachytherapy. BJU 2010; 106:809-814.

Fang, LC, Merrick GS, Wallner KE. Androgen Deprivation Therapy: A survival benefit or detriment in men with high-risk prostate cancer. Oncology 2010; 24:790-796.

Bittner N, Merrick GS, Galbreath RW, Butler WM, Adamovich E, Wallner KE. Greater biopsy core number is associated with improved biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2010; 78:1104-1110.

Sylvester JE, Grimm PD, Wong J, Merrick GS, Galbreath RW, Blasko JC. 15-year biochemical relapse-free survival, and overall survival following I-125 prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol Phys 2010; 81:376-381.

Merrick GS, Butler WM, Galbreath RW, Lief J, Bittner N, Wallner KE, Adamovich E. Prostate cancer death is unlikely in high risk patients following quality permanent interstitial brachytherapy. BJU 2011; 107:226-233.

Butler WM, Stewart RR, Merrick GS. Evaluation of radiobiologic biochemical control in a large permanent prostate brachytherapy population from a single institution using AAPM TG-137 parameters. Brachytherapy 2011; 10:16-28.

Merrick GS, Sylvester J, Grimm P, Allen ZA, Butler Wayne M, Reed JL, Khanjian J. Post-implant rectal dosimetry is not dependent on Pd-103 or I-125 seed activity. Brachytherapy 2011; 10:35-43.

Expert Panel on Radiation Oncology-Prostate: Rossi CJ, Merrick GS, Hsu I-Chow, Abdel-Wahab M, Arterbery VE, Ciezki JP, Frank SJ, Hahn NM, Mohler JL, Moran BJ, Rosenthal SA. ACR Appropriateness Criteria postradical prostatectomy irradiation in prostate cancer. Am J Clin Oncol 2011; 34:92-98.

Expert Panel on Radiation Oncology-Prostate: Moran BJ, DeRose P, Hsu I-Chow, Abdel-Wahab M, Arterber VE, Ciezki Jp, Frank SJ, Mohler JL, Rosenthal SA, Rossi CJ, Yamada Y, Merrick GS. ACR Appropriateness Criteria® Definitive External Beam Irradiation in Stage T1 and T2 Prostate Cancer. Am J Clin Oncol 2011; 34:636-647.

Expert panel on Radiation Oncology-Prostate: Frank SJ, Arterbery E, Merrick GS, Hsu CJ, Abdel-Wahab M, Ciezki JP, Hahn NM, Mohler JL, Moran BJ, Rosenthal SA, Rossi CJ, Yamada Y. American College of Radiology Appropriateness Criteria permanent source brachytherapy for prostate cancer. Brachytherapy 2011; 10:357-362.

Aronowitz JN, Crook JM, Merrick GM, Michalski JM, Sylvester JE, Mawson C, Pratt D, Naidoo D, Karolczuk K, Butler WM. The role of nomograms for prostate brachytherapy in the era of computer and intra-operative dosimetry. Am J Clin Oncol, in press.

Aronowitz JN, Michalski JM, Merrick GS, Sylvester JE, Crook JM, Butler WM, Mawson C, Pratt D, Naidoo D, Karolczuk K. Optimal equations for describing the relationship between prostate volume, number of sources, and total activity in permanent prostate brachytherapy. Am J Clin Oncol 2010; 33:164-167.

Bittner N, Butler WM, Reed JL, Murray BC, Kurko BS, Wallner K, Merrick GS. Electromagnetic tracking of intrafraction prostate displacement among patients externally immobilized in the prone position. Int J Radiat Oncol Biol Phys 2010;77:490-495.

Bittner N, Merrick GS, Stewart R, Andreini H, Taubenslag W, Curtis R, Butler W, Wallner K. Obesity does not correlate with adverse pathologic findings on transperineal template-guided mapping biopsy of the prostate. Urol Oncol 2011; 29:398-404.

Taira AV, Merrick GS, Butler WM, Galbreath RW, Lief J, Adamovich E, Wallner KE. Long-term outcome for clinically localized prostate cancer treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2011; 79:1336-1342.

Fang LC, Merrick GS, Butler WM, Galbreath RW, Murray BC, Reed J, Adamovich E, Wallner KE. High-risk prostate cancer with gleason score 8-10 and psa ≤15 treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2011; 81:992-996.

Bittner N, Merrick GS, Butler WM, Allen ZA, White B, Adamovich A, Wallner K. The correlation between annular treatment margins and biochemical failure. Int J Radiat Oncol Biol Phys 2011; 10:409-415.

Grimm P, Billiet I, Bostwick D, Crawford D, Dicker A, Frank S, Immerzeel J, Keyes M, Kupelian P, Lee R, Machtens S, Mayadev J, Moran B, Merrick G, Millar J, Roach M, Stock R, Shinohara K, Scholz M, Weber E, Zietman A, Zelefsky M, Wong J, Wentworth S, Vera R, Langley S. Comparative analysis of PSA free survival outcomes for patients with low, intermediate, and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJUI Supplements 2012; 109:22-29.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Lief J, Adamovich E, Wallner KE. Distant metastases following permanent interstitial brachytherapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82:e225-e232.

Bittner N, Merrick GS, Galbreath RW, Butler WM, Lief J, Allen ZA, Wallner KE. Erectile dysfunction is predictive of all-cause mortality in prostate cancer patients treated with permanent interstitial brachytherapy. BJU 2012; 109:220-225.

Ciezki JP, Hsu IC, Abdel-Wahab M, Arterbery VE, Frank SJ, Mohler JL, Moran BJ, Rosenthal SA, Rossi CJ, Yamada Y, Merrick G. American College of Radiology Appropriateness Criteria - locally advanced (High-risk) prostate cancer. Clinical Oncology 2011; 24:43-51.

Davis BJ, Horwitz EM, Lee WR, Crook JM, Stock RG, Merrick GS, Butler WM, Grimm PD, Stone NN, Potters L, Zietman AL, Zelefsky MJ. American Brachytherapy Society Recommendations for Transrectal Ultrasound Guided Permanent Prostate Brachytherapy. Brachytherapy 2011; 11:6-19.

Merrick GS, Wallner KE, Butler WM, Galbreath RW, Taira AV, Orio P, Adamovich E. 20Gy vs. 44Gy of supplemental external beam radiation with Pd-103 for patients with higher risk disease: Results of a prospective randomized trial. Int J Radiat Oncol Biol Phys 2012; 82:e449-e455.

Merrick GS, Lief JH, Grimm P, Sylvester J, Butler WM, Allen ZA. The effect of Pro-Qura case volume on post-implant prostate dosimetry. Int J Radiat Oncol Biol Phys 2011; 81:e727-e734.

Patel V, Merrick GS, Allen ZA, Andreini H, Taubenslag W, Singh S, Butler WM, Adamovich E, Bittner N. The incidence of transition zone prostate cancer diagnosed by transperineal template guided mapping biopsy: Implications for treatment planning. Urology 2011, 77:1148-1152.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Lief J, Allen ZA, Wallner KE. Serum testosterone kinetics following brachytherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2012; 82:e33-e38.

Wahab MA, Mahmoud O, Hsu IJ, Arterbery VE, Ciezki JP, Frank SJ, Mohler JL, Moran BJ, Rosenthal SA, Rossi CJ, Yamada Y, Merrick G. ACR Appropriateness Criteria external beam radiation therapy treatment planning for clinically localized prostate cancer. Amer Coll of Rad 2012; 9:233-238.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Bennett A, Adamovich E, Lief JH, Wallner KE. Prognostic importance of tobacco use in men receiving definitive prostate brachytherapy. Brachytherapy 2012; 11:446-451.

Butler WM, Morris MN, Merrick GS, Kurko BS, Murray BC. Effect of body mass index on intrafraction prostate displacement monitored by real-time electromagnetic tracking. Int J Radiat Oncol Biol Phys 2012; 84:e173-e179.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Adamovich E, Wallner KE. Prognostic importance of small prostate size in men receiving definitive prostate brachytherapy. Amer J Clin Oncol 2012;84:396-401.

Orio PF, Merrick GS, Galbreath RW, Butler WM, Lief J, Wallner KE. Patient reported long-term rectal function after permanent interstitial brachytherapy for clinically localized prostate cancer. Brachytherapy 2012;11:341-347.

Bittner N, Merrick GS, Butler WM, Galbreath RW, Anderson R, Adamovich E, Wallner KE. Higher percentage of positive biopsy cores and Gleason score are associated with a greater degree of prostate gland shrinkage following neoadjuvant cytoreductive therapy. Brachytherapy 2012;11:219-223.

Butler WM, Merrick GS, Reed JL, Kurko BS, Murray BC. Intrafraction displacement of prone versus supine patient positioning on intrafraction prostate displacement monitored by real-time electromagnetic tracking. Journal of Applied Clinical Medical Physics, 2013; 14:198-208.

Shilkrut M, McLaughlin WP, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Merrick GS, Hamstra DA. The addition of low dose rate brachytherapy and androgen deprivation therapy decreases prostate cancer death compared to dose escalated external beam radiation therapy for high-risk prostate cancer. Int J Radiat Oncol Biol Phys 2012; 84:S149.

Taira AV, Merrick GS, Grimm P, Butler WM, Lief JH, Morris M, Bennett A. Impact of small prostate size on post-implant prostate dosimetry: Analysis of a large community database. Brachytherapy 2013; 12:222-227.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Lief JH, Adamovich E, Wallner KE. Long-term outcomes of prostate cancer patients with Gleason pattern 5 treated with combined brachytherapy and external beam radiotherapy. Brachytherapy 2013; 12:408-414.

Bittner N, Merrick GS, Butler WM, Galbreath RW, Adamovich E, Wallner KE. Gleason score 7 prostate cancer treated with intersitital brachytherapy with or without supplemental external beam radiation and androgen deprivation therapy: is the primary pattern on needle biopsy prognostic? Brachytherapy 2013; 12:14-18.

Merrick GS, Butler WM, Grimm P, Morris M, Lief JH, Bennett A, Fiano R. Permanent prostate brachytherapy extracapsular radiation dose distributions: Analysis of a multi-institutional database. Journal of Contemporary Brachytherapy 2013; 5,3:117-121

Shetti MB, Merrick GS, Butler WM, Galbreath R, Torlone A, Lief JH, Adamovich E, Wallner KE. The impact of diabetes mellitus on survival in men with clinically localized prostate cancer treated with permanent interstitial brachytherapy. Amer J Clin Oncol 2012; 35:572-579.

Taira AV, Merrick GS, Bennett, A, Andreini H, Taubenslag W, Galbreath RW, Butler WM, Bittner N, Adamovich E. Transperineal template-guided mapping biopsy as a staging procedure to select patients best suited for active surveillance. Amer J Clin Oncol 2013; 36:116-120.

Bittner N, Merrick GS, Butler WM, Galbreath RW, Lief J, Adamovich E, Wallner KE. Long term outcome for very high-risk prostate cancer treated primarily with a triple modality approach to include permanent interstitial brachytherapy. Brachytherapy 2012; 11:250-255.

Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA. The addition of low dose rate brachytherapy and androgen deprivation therapy decreases biochemical failure and prostate cancer death compared to dose escalated external beam radiation therapy for high-risk prostate cancer. Cancer 2013; 119:681-690.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Fiano R, Wallner KE, Adamovich E. Time to failure after definitive therapy for prostate cancer: Implications for importance of aggressive local treatment. Journal of Contemporary Brachytherapy 2013; 5:215-221.

Eberhardt SC, Carter S, Casalino DD, Merrick GS, Frank SJ, Gottschalk AR, Leyendecker JR, Nguyen PL, Oto A, Porter C, Remer EM, Rosenthal SA. ACR Appropriateness Criteria. Prostate Cancer – Pretreatment Detection, Staging, and Surveillance. J Am Coll Radiol 2013; 10:83-92.

Shilkrut M, McLaughlin PW, Merrick GS, Vainshtein JM, Feng FY, Hamstra DA. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy. Int J Radiat Oncol Biol Phys. 2013; 86:721-728.

Bittner N, Merrick GS, Butler WM, Bennett A, Galbreath R. Incidence and pathologic features of prostate cancer detected on transperineal template-guided mapping biopsy following negative transrectal ultrasound-guided biopsy. J Urol 2013, 190:509-514.

Expert Panel on Radiation Oncology-Prostate: Nguyen PL, Aizer A, Assimos DG, Damico AV, Frank SJ, Gottschalk AR, Gustafson GS, Hsu IJ, McLaughlin PW, Merrick GS, Rosental SA, Showalter TN, Taira AV, Vapiwala N, Yamada Y, Davis BJ. Definitive External Beam Irradiation In Stage T1 and T2 Prostate Cancer. Amer J Clin Oncol 2014; 37:278-288.


Merrick GS, Butler WM, Grimm P, Morris M, Lief JH, Bennett A, Fiano R. Multi-sector prostate dosimetric quality: analysis of a large community database. Brachytherapy 2014, 13:146-51.

Bittner N, Merrick GS, Bennett A, Butler WM, Andreini HJ, Taubenslag W, Adamovich A. Diagnostic performance of initial transperineal template-guided mapping biopsy of the prostate gland. Am J Clin Oncol 2015; 38:300-303.

Merrick GS, Delatore A, Butler WM, Bennett A, Fiano R, Anderson R, Adamovich E. Transperineal Template guided mapping biopsy identifies pathologic differences between very low and low risk prostate cancer: implications for active surveillance. AJCO 2014, epub ahead of print.

Hsu IJ, Yamada Y, Assimos DG, D’AmicoAV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick GS. ACR Appropriateness Criteria High-Dose-Rate Brachytherapy for Prostate Cancer. Brachytherapy 2014; 13:27-31.

Taira AV, Merrick GS, Galbreath RW, Morris M, Butler WM, Adamovich A. Metformin is not associated with improved biochemical free survival or cause-specific survival in men with prostate cancer treated with permanent interstitial brachytherapy. Journal of Contemporary Brachytherapy 2014; 6:254-261.

Bittner N, Butler WM, Kurko BS, Merrick GS. Effect of metal hip prosthesis on the accuracy of electromagnetic localization tracking. PRO 2015; 5:43-48.

Expert Panel on Radiation Oncology-Prostate: Gustafson GS, Davis BJ, Nguyen PL, Assimos DG, D’Amico AV, Gottschalk AR, Hsu IJ, Lloyd S, McLaughlin PW, Merrick GS, Showalter TN, Taira AV, Vapiwala N, Yamada Y. Postradical prostatectomy irradiation in prostate cancer. Oncology 2014; 1125-1136.

Wallner K, Sutlief S, Bergsagel C, Merrick GS. Severe rectal complications after prostate brachytherapy. Radiotherapy and Oncology 2015; 114:272-275.

Merrick GS, Wallner KE, Galbreath RW, Butler WM, Fiano R, Orio PF, Adamovich E. Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with Pd-103? Results of two prospective randomized trials. Brachytherapy 2015; 14:677-685.

Bittner N, Merrick GS, Galbreath RW, Butler WM, Adamovich E. Treatment outcomes with permanent brachytherapy in high-risk prostate cancer patients stratified into prognostic categories. Brachytherapy 2015; 14:766-772.

Merrick GS, Wallner K, Galbreath R, Butler WM, Adamovich E. Is supplemental external beam radiation therapy essential to maximize brachytherapy outcomes in patients with unfavorable intermediate-risk disease? Brachytherapy 2016; 15:79-84.

Shilkrut M, McLaughlin PW, Merrick GS, Vainshtein JM, Hamstra DA. Treatment outcomes in very high risk prostate cancer treated by dose-escalated and combined-modality radiation therapy. Am J Clin Oncol 2016; 39:181-188.

Merrick GS, Butler WM, Galbreath RW, Fiano R, Adamovich E. Stratification of brachytherapy-treated intermediate-risk prostate cancer patients into favorable and unfavorable cohorts. Journal of Contemporary Brachytherapy 2016; 7:430-436.

Merrick GS, Galbreath RW, Bennett A, Butler WM, Adamovich E. Incidence, grade and distribution of prostate cancer following transperineal template-guided mapping biopsy in patients with atypical small acinar proliferation. World J of Urol 2017, 35:1009-1013.

Merrick GS, Bennett A, Courture T, Butler WM, Galbreath RW, Adamovich E. Metformin does not predict for prostate cancer diagnosis, grade, or volume of disease following transperineal template-guided mapping biopsy. Amer J Clin Oncol 2015, in press.

Butler WM, Merrick GS. Focal Prostate Brachytherpay with Pd-103 seeds. European Journal of Medical Physics 2016, in press.

Bittner N, Merrick G, Orio PF, Prestige BR, Harford AC, Rosenthal SA. ACR-ABS practice parameter for transperineal permanent brachytherapy of prostate cancer. Brachytherapy 2017, 16: 59-67.

Foster B, Liauw S, McNamara A, Chan J, McLaughlin W, Feng F, Merrick GS, Hamstra D. Application of a prognostic stratification system for high-risk prostate cancer to patients treated with radiotherapy and comparison of treatment outcomes to radical prostatectomy. 2015, Submitted.

Merrick GS, Irvin S, Fiano R, Anderson R, Butler WM, Adamovich E. Pathology and Quality of Life Outcomes Following Office Based Transperineal Prostate Biopsy. Urology 2016, in press.

Taira AV, Merrick GS, Galbreath RW, Butler WM, Adamovich E. Impact of androgen deprivation therapy on overall mortality in prostate brachytherapy patients with low pre-treatment testosterone levels. AJCO 2016, in press.

Fiano RM, Merrick GS, Butler WM, Galbreath RW. Transperineal mapping prostate biopsy and depressive symptoms: associations with demographic and clinical variables at day 30 post-biopsy. 2016, Submitted.

Bittner N, Merrick GS, Taira A, Bennett A, Schattel A, Butler W, Galbreath R, Adamovich E. Location and grade of prostate cancer diagnosed by transperineal template guided mapping biopsy after negative transrectal ultrasound guided biopsy. AJCO 2016, in press.

Keyes M, Merrick GS, Frank SJ, Grimm P, Zelefsky MJ. Use of androgen deprivation therapy with prostate brachytherapy, a systematic literature review. Brachytherapy 2017, epub ahead of print.

Merrick GS, Tennant A, Wallner KE, Galbreath R, Butler WM, Fiano R, Adamovich E. Does supplemental external beam radiation therapy impact urinary, bowel and erectile function following permanent prostate brachytherapy?: Results of two prospective randomized trials. 2017, Submitted.


 


home
about
our people
scientific publications
research resources
patient resources
news
special projects
doante
contact us
wheeling hospital